Data as of Aug 29
| +0.16 / +1.37%|
The 10 analysts offering 12-month price forecasts for ImmunoGen Inc have a median target of 14.00, with a high estimate of 21.00 and a low estimate of 10.00. The median estimate represents a +18.44% increase from the last price of 11.82.
The current consensus among 13 polled investment analysts is to Hold stock in ImmunoGen Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.